Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO -4.22%61 Receivables Turnover is 2.20 as of Jun. 2026. GuruFocus rates TKNO with a GF Score™ of 61/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, Alpha Teknova ranks better than 80.89% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Alpha Teknova's Revenue for the
three
months ended in Jun. 2026 was $12.19 Mil. Alpha Teknova's average Accounts Receivable for the
three
months ended in Jun. 2026 was $5.54 Mil.
Hence, Alpha Teknova's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.20.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Alpha Teknova Receivables Turnover Related Terms
Alpha Teknova Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TKNO vs NIKA, BIOA, ELTP: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a Receivables Turnover of 2.20 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alpha Teknova and its competitors. According to the industry distribution chart, Alpha Teknova ranks #181 out of 947 companies in the Drug Manufacturers industry, placing it in the top 19.1%.
Is Alpha Teknova's Receivables Turnover too high?
Alpha Teknova's current Receivables Turnover is 2.20. The Drug Manufacturers industry median Receivables Turnover is 5.08. Alpha Teknova's value of 2.20 is 56.7% below this industry median. Based on the distribution chart, Alpha Teknova ranks #181 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alpha Teknova has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's Receivables Turnover compare to NIKA and BIOA?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #181 out of 947 companies for Receivables Turnover. This places Alpha Teknova in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.08. Alpha Teknova's value of 2.20 is 56.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Teknova's current Receivables Turnover of 2.20 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current Receivables Turnover is 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.92 — trading 55.5% above its estimated fair value. The current Receivables Turnover is 2.20 and 56.7% below the Drug Manufacturers industry median of 5.08. Alpha Teknova's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current Receivables Turnover is 2.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $6.92 is trading 55.5% above its estimated GF Value™ of $4.45.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
Receivables Turnover: 2.20
GF Value™: $4.45 vs. price of $6.92 (55.5% above fair value)
Industry Position: 56.7% below the Drug Manufacturers median (#181 of 947)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
61GF Score
Get the complete analysis for TKNO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
